Here are the 424B prospectus supplements from Clene Inc. Warrant (CLNNW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLNNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLNNW filings page.
Clene Inc. is offering 1,000,000 shares of common stock at an offering price of $7.00 per share pursuant to this prospectus supplement and the accompanying base prospectus. Delivery is expected on or about May 6, 2026. Net proceeds to the company are estimated at approximately $6,405,000 after underwriting discounts. The company states it will use proceeds to prepare and file an NDA for CNM-Au8, support ongoing expanded access protocols and a planned Phase 3 trial, expand manufacturing, and for general corporate purposes. The filing discloses substantial doubt about Clene’s ability to continue as a going concern: cash and cash equivalents were $5.2M as of December 31, 2025, operating losses were $23.1M for 2025, and the company expects to need additional financing within the next twelve months. The prospectus supplement also summarizes recent FDA feedback that NfL biomarker changes “may be capable of supporting” an NDA submission under the accelerated approval pathway in ALS and states the company intends to submit an NDA in Q3 2026.
Clene Inc. files a preliminary prospectus supplement under its Form S-3 shelf to offer shares of common stock (Nasdaq: CLNN), with aggregate shelf capacity of $160,000,000. The supplement does not state the number of shares or the public offering price per share; delivery and certain dates are left blank in this draft. The prospectus supplement describes use of proceeds for general corporate purposes, including funding clinical development of CNM-Au8, manufacturing and regulatory activities, and early-stage R&D.
The company reported 11,778,307 shares outstanding as of April 30, 2026. Financial context includes a loss from operations of $23.1M and cash and cash equivalents of $5.2M as of December 31, 2025, and the filing discloses substantial doubt about going concern and plans to seek additional financing.